Diabetic Cardiomyopathies Clinical Trial
Official title:
Evaluation of Alpha-Lipoic Acid in Diabetic Cardiomyopathy
The heart has the ability to respond to different patho-physiological conditions by adapting its energy metabolism. In diabetic subjects, the myocardium uses only fatty acids as a substrate. This is the cause of diabetic cardiomyopathy (DCM). The activation of the transcription factor PPARβ/δ allows a good use of fatty acids. The staff have demonstrated that alpha lipoic acid (AαL), a molecule with antioxidant properties present in food supplements and in certain foods (broccoli, cabbage, offal...), induces the expression of PPARβ/δ in skeletal muscle and thus increases the activity of this transcription factor.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04083339 -
Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy
|
Phase 3 | |
| Recruiting |
NCT05556005 -
Efficacy of Trimetazidine in Diabetic Patients
|
Phase 2 | |
| Completed |
NCT03299790 -
Effect of High-intensity Interval Training on Cardiac Function and Regulation of Glycemic Control in Diabetic Cardiomyopathy
|
N/A | |
| Recruiting |
NCT03132129 -
Prevalence and Determinants of Subclinical Cardiovascular Dysfunction in Adults With Type 2 Diabetes Mellitus
|
||
| Recruiting |
NCT04593173 -
Diabetic Cardiomyopathy
|
||
| Not yet recruiting |
NCT04534894 -
Single-center Clinical Study of Early Diagnosis of Diabetic Cardiomyopathy With FLIM
|
||
| Completed |
NCT03049228 -
In and ex Vivo Mitochondrial Function of the Heart
|
||
| Completed |
NCT03930004 -
Preclinical Cardiomyopathy and Autonomic Function in Type 1 Diabetes
|
||
| Not yet recruiting |
NCT05571865 -
Diabetic Cardiomyopathy and Heart Failure
|
N/A | |
| Recruiting |
NCT05958706 -
Mitochondrial Substrate Utilization in the Diabetic Human Heart
|
||
| Recruiting |
NCT04591639 -
The DAPA-MEMRI Trial
|
N/A | |
| Recruiting |
NCT04826159 -
IMPROVE-DiCE: Study to Evaluate Effect of IMB-1018972 on Cardiac Energetics in T2DM & Obesity (Pt 1) With HFpEF (Pt 2)
|
Phase 2 | |
| Enrolling by invitation |
NCT05915260 -
CMR in T2DM: The NSR Cohort
|